Press release
Primary Catalyst Driving Neuroblastoma Market Evolution in 2025: Rising Childhood Cancer Incidence Driving Growth In The Market Driver
Neuroblastoma Market Size
Recent years have seen robust growth in the neuroblastoma market size. Predictions suggest an escalation from $2.97 billion in 2024 to $3.15 billion in 2025, marking a compound annual growth rate (CAGR) of 6.1%. The historical growth is due largely to a rise in neuroblastoma prevalence, heightened research and development for pediatric neuroblastoma treatments, an increasing incidence of childhood cancer, as well as greater funding and governmental support.
In the coming years, the neuroblastoma market is anticipated to witness a solid growth, reaching a net worth of $3.93 billion in 2029, with an annual growth rate (CAGR) of 5.7%. This growth trajectory in the forecast period can be attributed to several factors such as greater investment by the government, rise in the occurrence rate of the disease, enhanced emphasis on early diagnosis, increased prevalence of genetic variations, and emerging comprehension and advancements in research. Precise molecular pathway targeted drug development, innovative non-invasive imaging technologies, progress in gene-editing technologies, increased concentration on personalized remedies and the creation of radiolabeled compounds are considered the major trends in the forecast period.
What Is Stimulating Growth in the Neuroblastoma Market?
The escalation in childhood cancer occurrences is anticipated to fuel the expansion of the neuroblastoma market. This form of cancer, which primarily impacts children and adolescents, affects vital organs such as the brain, blood, and bones, necessitating unique treatment methods. The surge in childhood cancer cases is linked to improved diagnostics, increased awareness, environmental exposures, genetic propensities, and medical research advancements. Neuroblastoma care offers precise treatments for childhood cancer, enabling swift and effective actions leading to reduced chances of relapse and better health outcomes for children. For example, the American Cancer Society, a US-based professional organization, reported in May 2024 that around 9,620 under-15 children in America will be identified with cancer in 2024, up from 5,290 cases in 2023. Hence, the climb in childhood cancer cases is serving to promote the growth of the neuroblastoma market.
Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20901&type=smp
Which Key Market Leaders Are Driving Neuroblastoma Industry Growth?
Major companies operating in the neuroblastoma market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Eli Lilly and Company, Sartorius AG, Recordati S.p.A, United Therapeutics Corporation, BeiGene Ltd., MacroGenics Inc., Y-mAbs Therapeutics Inc., RedHill Biopharma Ltd., Clarity Pharmaceuticals Ltd., EUSA Pharma (UK) Ltd., US WorldMeds LLC, Healio Inc., Ascentage Pharma, Laboratorio Elea Phoenix S.A, Curis Inc., PersonGen BioTherapeutics (Suzhou) Co. Ltd., Essential Pharma S.A, Cellectar Biosciences Inc., Provectus Biopharmaceuticals Inc.
What Are the Emerging Trends in the Neuroblastoma Industry?
Prominent businesses in the neuroblastoma sector are heavily investing in creating highly sophisticated treatment tactics, like humanized anti-GD2 monoclonal antibodies, to target and eliminate cancer cells with increased effectiveness and lowered risk. Humanized anti-GD2 monoclonal antibodies are designed to attach to the GD2 molecule on cancer cells while limiting immune system rejection by integrating human elements. For example, Renaissance Pharma Ltd, a UK clinical-stage pharmaceutical firm, acquired the license for Hu14.18K322A (Hu14.18) from St. Jude Children's Research Hospital in August 2023. This engineered antibody is intended to target newly diagnosed high-risk neuroblastoma, a severe and rapidly progressing pediatric cancer. As per the deal, Renaissance now holds the exclusive rights to produce, refine and distribute Hu14.18 in major international markets such as the United States, Canada, Europe, China, Japan, and Turkey.
What Are the Main Segments in the Neuroblastoma Market?
The neuroblastoma market covered in this report is segmented -
1) By Product Types: Tablets, Vaccines, Other Product Types
2) By Treatment Type: Chemotherapy, Immunotherapy, Other Treatment Types
3) By Distribution Channel: Online, Offline
4) By End-User: Hospitals, Clinics
Subsegments:
1) By Tablets: Oral Chemotherapy Tablets, Targeted Therapy Tablets
2) By Vaccines: Immunotherapy Vaccines, Therapeutic Vaccines
3) By Other Product Types: Injectable Drugs, Monoclonal Antibodies, Cell Therapy Products
Pre-Book Your Report Now For A Swift Delivery:
https://www.thebusinessresearchcompany.com/report/neuroblastoma--global-market-report
Which Geographic Area Leads the Neuroblastoma Market?
North America was the largest region in the neuroblastoma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neuroblastoma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Is Covered In The Neuroblastoma Global Market Report?
- Market Size Analysis: Analyze the neuroblastoma Market size by key regions, countries, product types, and applications.
- Market Segmentation Analysis: Identify various subsegments within the neuroblastoma Market for effective categorization.
- Key Player Focus: Focus on key players to define their market value, share, and competitive landscape.
- Growth Trends Analysis: Examine individual growth trends and prospects in the market.
- Market Contribution: Evaluate contributions of different segments to the overall neuroblastoma market growth.
- Growth Drivers: Detail key factors influencing market growth, including opportunities and drivers.
- Industry Challenges: Analyze challenges and risks affecting the neuroblastoma market.
- Competitive Developments: Analyze competitive developments, such as expansions, agreements, and new product launches in the market.
Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20901
"
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
•LinkedIn: https://in.linkedin.com/company/the-business-research-company
•Twitter: https://twitter.com/tbrc_info
•YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
About The Business Research Company
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Primary Catalyst Driving Neuroblastoma Market Evolution in 2025: Rising Childhood Cancer Incidence Driving Growth In The Market Driver here
News-ID: 3875885 • Views: …
More Releases from The Business Research Company
Emerging Trends to Reshape the Surgical Energy Instruments Market: Innovative Te …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Surgical Energy Instruments Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
In the past few years, the market size of surgical energy instruments has seen substantial growth. The market which is projected to be worth $4.68 billion in 2024, is expected to inflate to $5.2…
2025-2034 Spatial omics Market Evolution: Disruptions, Innovations, and Untapped …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Is the Expected CAGR for the Spatial omics Market Through 2025?
In recent years, the size of the spatial omics market has seen rapid expansion. The estimations show an increase to $0.33 billion in 2025 from $0.3 billion in 2024, marking a compound annual growth rate (CAGR) of…
Global Sigmoidoscope Market Projected to Grow at 6.1% CAGR, Reaching $3.38 Billi …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Will the Sigmoidoscope Industry Market Size Be by 2025?
In recent years, there has been a significant increase in the size of the sigmoidoscope market. The market is projected to expand from $2.53 billion in 2024 to $2.67 billion in 2025, demonstrating a compound annual growth rate (CAGR)…
2025-2034 Refurbished MRI Systems Market Roadmap: Insights for Competitive Advan …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
How Large Will the Refurbished MRI Systems Market Size By 2025?
The market size for refurbished MRI systems has experienced robust growth in the past few years. It is expected to rise from $0.77 billion in 2024 to $0.85 billion in 2025, showcasing a compound annual growth rate (CAGR)…
More Releases for Neuroblastoma
Pediatric Neuroblastoma Market to Reach USD 2.6 Billion by 2034
Neuroblastoma is the most common extracranial solid tumor in children, typically affecting infants and young children under the age of five. Arising from immature nerve cells of the sympathetic nervous system, neuroblastoma accounts for approximately 8-10% of all childhood cancers but represents a significant share of pediatric oncology deaths due to its aggressive nature.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71561
Historically, treatment has relied on surgery, chemotherapy, and…
Neuroblastoma Market Massive Growth opportunity Ahead
Neuroblastoma market Size, Status, and Forecast for the 2025-2034. In-depth research has been compiled to provide the most up-to-date information on key aspects of the worldwide market. This research report covers major aspects of the Neuroblastoma Market including drivers, restraints, historical and current trends, regulatory scenarios, and technological advancements. It provides the industry overview with growth analysis and historical & futuristic cost, revenue, demand and supply data (as applicable). The…
Pediatric Neuroblastoma Treatment Market - Redefining Possibilities: Advancement …
Newark, New Castle, USA: The "Pediatric Neuroblastoma Treatment Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Pediatric Neuroblastoma Treatment Market: https://www.growthplusreports.com/report/pediatric-neuroblastoma-treatment-market/7681
This latest report researches the industry structure,…
Neuroblastoma Treatment Market Projected to Garner Significant Revenues by 2024
Neuroblastoma is the most common type of cancer in infants. The cancer is caused as a result of embryonal malignancy of sympathetic nervous system which arises from the neuroblasts. The cancer develops in the nerve tissues of adrenal, chest or spinal cord. Neuroblastoma is listed as a “rare disease” in the U.S. by the National Institute of Health (NIH), and Orphanet in Europe. The cancer is most prevalent in infants…
Neuroblastoma Drugs Market Size, Share, Development by 2024
New report published by Global Info Research which offers insights on the Global Neuroblastoma Drugs market.
Neuroblastoma (NB) is a type of cancer that forms in certain types of nerve tissue. It most frequently starts from one of the adrenal glands, but can also develop in the neck, chest, abdomen, or spine. Symptoms may include bone pain, a lump in the abdomen, neck, or chest, or a painless bluish lump under…
Global Neuroblastoma Treatment Market: Latest Trends and Insights 2023
Neuroblastoma is the most common type of cancer in infants. The cancer is caused as a result of embryonal malignancy of sympathetic nervous system which arises from the neuroblasts. The cancer develops in the nerve tissues of adrenal, chest or spinal cord. Neuroblastoma is listed as a “rare disease” in the U.S. by the National Institute of Health (NIH), and Orphanet in Europe. The cancer is most prevalent in infants…
